glp 1 agonist saxenda (liraglutide) for the Treatment of Obesity, US FDA Approves First Generic GLP-1
Description
Early preclinical studies focused on mice that develop diet-induced liver inflammation alongside atherosclerosis
These promote pancreatic-cell development and differentiation, decrease islet-cell activity, and increase insulin production
A drug that produces greater average weight loss may not deliver better outcomes if it is less well tolerated by a specific patient
Eli Lilly is banking on its experimental pill to entice potential users
GLP-1 Receptor Agonists Genotype Report: Access this content: An active subscription is required to access this content
Diabetes Care 37 , 19381943 (2014)
